These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15173010)

  • 1. Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models.
    Manne V; Lee FY; Bol DK; Gullo-Brown J; Fairchild CR; Lombardo LJ; Smykla RA; Vite GD; Wen ML; Yu C; Wong TW; Hunt JT
    Cancer Res; 2004 Jun; 64(11):3974-80. PubMed ID: 15173010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor.
    Rose WC; Lee FY; Fairchild CR; Lynch M; Monticello T; Kramer RA; Manne V
    Cancer Res; 2001 Oct; 61(20):7507-17. PubMed ID: 11606387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells.
    Marzo I; Pérez-Galán P; Giraldo P; López-Royuela N; Gómez-Benito M; Larrad L; Lasierra P; Rubio-Félix D; Anel A; Naval J
    Leukemia; 2004 Oct; 18(10):1599-604. PubMed ID: 15356656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity.
    Hunt JT; Ding CZ; Batorsky R; Bednarz M; Bhide R; Cho Y; Chong S; Chao S; Gullo-Brown J; Guo P; Kim SH; Lee FY; Leftheris K; Miller A; Mitt T; Patel M; Penhallow BA; Ricca C; Rose WC; Schmidt R; Slusarchyk WA; Vite G; Manne V
    J Med Chem; 2000 Oct; 43(20):3587-95. PubMed ID: 11020273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Requirement of c-jun N-terminal kinase for apoptotic cell death induced by farnesyltransferase inhibitor, farnesylamine, in human pancreatic cancer cells.
    Mizukami Y; Ura H; Obara T; Habiro A; Izawa T; Osanai M; Yanagawa N; Tanno S; Kohgo Y
    Biochem Biophys Res Commun; 2001 Oct; 288(1):198-204. PubMed ID: 11594773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination.
    Gómez-Benito M; Marzo I; Anel A; Naval J
    Mol Pharmacol; 2005 Jun; 67(6):1991-8. PubMed ID: 15738311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical and clinical evaluation of farnesyltransferase inhibitors.
    Baum C; Kirschmeier P
    Curr Oncol Rep; 2003 Mar; 5(2):99-107. PubMed ID: 12583826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.
    Lombardo LJ; Camuso A; Clark J; Fager K; Gullo-Brown J; Hunt JT; Inigo I; Kan D; Koplowitz B; Lee F; McGlinchey K; Qian L; Ricca C; Rovnyak G; Traeger S; Tokarski J; Williams DK; Wu LI; Zhao Y; Manne V; Bhide RS
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1895-9. PubMed ID: 15780629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyltransferase inhibitors.
    Hahn SM; Bernhard E; McKenna WG
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):86-93. PubMed ID: 11706400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and structure-activity relationships of imidazole-containing tetrahydrobenzodiazepine inhibitors of farnesyltransferase.
    Ding CZ; Batorsky R; Bhide R; Chao HJ; Cho Y; Chong S; Gullo-Brown J; Guo P; Kim SH; Lee F; Leftheris K; Miller A; Mitt T; Patel M; Penhallow BA; Ricca C; Rose WC; Schmidt R; Slusarchyk WA; Vite G; Yan N; Manne V; Hunt JT
    J Med Chem; 1999 Dec; 42(25):5241-53. PubMed ID: 10602709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.
    Ryan DP; Eder JP; Puchlaski T; Seiden MV; Lynch TJ; Fuchs CS; Amrein PC; Sonnichsen D; Supko JG; Clark JW
    Clin Cancer Res; 2004 Apr; 10(7):2222-30. PubMed ID: 15073096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.
    Brassard DL; English JM; Malkowski M; Kirschmeier P; Nagabhushan TL; Bishop WR
    Exp Cell Res; 2002 Feb; 273(2):138-46. PubMed ID: 11822869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM; Lau N; Guha A
    Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
    Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival.
    Shi Y; Wu J; Mick R; Cerniglia GJ; Cohen-Jonathan E; Rhim JS; Koch CJ; Bernhard EJ
    Prostate; 2005 Jan; 62(1):69-82. PubMed ID: 15389805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors.
    Liu Ax; Du W; Liu JP; Jessell TM; Prendergast GC
    Mol Cell Biol; 2000 Aug; 20(16):6105-13. PubMed ID: 10913192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.
    Sun J; Blaskovich MA; Knowles D; Qian Y; Ohkanda J; Bailey RD; Hamilton AD; Sebti SM
    Cancer Res; 1999 Oct; 59(19):4919-26. PubMed ID: 10519405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.